Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes

Meijer, T.; Looijen-Salamon, Monika; Lok, Jasper; Heuvel, Michel van den; Tops, Bastiaan B.J.; Kaanders, J.H.A.M.; Span, Paul N.; Bussink, Johan

doi:10.1111/1759-7714.13226

Cited by 22 publications

(26 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both SUVcov and SUVmax showed an AUC of 0.65 (17). PET-CT is a great instrument for metabolic demonstration, and some studies presented a relationship between glucose metabolism and RAS status (31). In Pierre's research, SUVmax was the most distinct parameter for KRAS status; in patients with KRAS mutations, SUVmax summary, PET-CT is a direct demonstration of tumor metabolism but still cannot uncover the strong relationship between the parameters of SUV and KRAS status based on the current evidence.…”

Section: Discussionmentioning

confidence: 99%

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients

et al. 2021

View full text Add to dashboard Cite

Background and PurposeLocally advanced rectal cancer (LARC) is a heterogeneous disease with little information about KRAS status and image features. The purpose of this study was to analyze the association between T2 magnetic resonance imaging (MRI) radiomics features and KRAS status in LARC patients.Material and MethodsEighty-three patients with KRAS status information and T2 MRI images between 2012.05 and 2019.09 were included. Least absolute shrinkage and selection operator (LASSO) regression was performed to assess the associations between features and gene status. The patients were divided 7:3 into training and validation sets. The C-index and the average area under the receiver operator characteristic curve (AUC) were used for performance evaluation.ResultsThe clinical characteristics of 83 patients in the KRAS mutant and wild-type cohorts were balanced. Forty-two (50.6%) patients had KRAS mutations, and 41 (49.4%) patients had wild-type KRAS. A total of 253 radiomics features were extracted from the T2-MRI images of LARC patients. One radiomic feature named X.LL_scaled_std, a standard deviation value of scaled wavelet-transformed low-pass channel filter, was selected from 253 features (P=0.019). The radiomics-based C-index values were 0.801 (95% CI: 0.772-0.830) and 0.703 (95% CI: 0.620-0.786) in the training and validation sets, respectively.ConclusionRadiomics features could differentiate KRAS status in LARC patients based on T2-MRI images. Further validation in a larger dataset is necessary in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To achieve this, glucose transporters are overexpressed in cancer cells to ensure glucose transportation for oncogenic transformation and progression. Regarding SCC, the histopathological subtype can be indicated by high expression of glucose transporter 1 (GLUT1) (38,39), e.g., premalignant lesions of bronchial epithelium (40), which can be reflected by a high SUV in PET images. For ADC, the mass can consist of different levels of cell differentiation to demonstrate heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

Habitat Imaging-Based 18F-FDG PET/CT Radiomics for the Preoperative Discrimination of Non-small Cell Lung Cancer and Benign Inflammatory Diseases

et al. 2021

View full text Add to dashboard Cite

PurposeTo propose and evaluate habitat imaging-based 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) radiomics for preoperatively discriminating non-small cell lung cancer (NSCLC) and benign inflammatory diseases (BIDs).MethodsThree hundred seventeen 18F-FDG PET/CT scans were acquired from patients who underwent aspiration biopsy or surgical resection. All volumes of interest (VOIs) were semiautomatically segmented. Each VOI was separated into variant subregions, namely, habitat imaging, based on our adapted clustering-based habitat generation method. Radiomics features were extracted from these subregions. Three feature selection methods and six classifiers were applied to construct the habitat imaging-based radiomics models for fivefold cross-validation. The radiomics models whose features extracted by conventional habitat-based methods and nonhabitat method were also constructed. For comparison, the performances were evaluated in the validation set in terms of the area under the receiver operating characteristic curve (AUC). Pairwise t-test was applied to test the significant improvement between the adapted habitat-based method and the conventional methods.ResultsA total of 1,858 radiomics features were extracted. After feature selection, habitat imaging-based 18F-FDG PET/CT radiomics models were constructed. The AUC of the adapted clustering-based habitat radiomics was 0.7270 ± 0.0147, which showed significantly improved discrimination performance compared to the conventional methods (p <.001). Furthermore, the combination of features extracted by our adaptive habitat imaging-based method and non-habitat method showed the best performance than the other combinations.ConclusionHabitat imaging-based 18F-FDG PET/CT radiomics shows potential as a biomarker for discriminating NSCLC and BIDs, which indicates that the microenvironmental variations in NSCLC and BID can be captured by PET/CT.

show abstract

“…SqCC is characterized by high expression of GLUT1 in almost all cases [ 214 , 215 , 216 , 217 ], from the premalignant lesions of bronchial epithelium [ 213 ] to metastatic cancer ( Figure 5 A,B). GLUT1 is upregulated in SqCC by p63, the lineage factor of basal bronchial epithelial cells, and Sox2 [ 5 ], and is associated with SqCC vulnerability to glucose restriction by pharmacological inhibition of GLUT1 [ 4 ].…”

Section: Heterogeneity Of Glucose Transporters In Lung Cancermentioning

confidence: 99%

Heterogeneity of Glucose Transport in Lung Cancer

Rivera

Scafoglio

2020

Biomolecules

View full text Add to dashboard Cite

Increased glucose uptake is a known hallmark of cancer. Cancer cells need glucose for energy production via glycolysis and the tricarboxylic acid cycle, and also to fuel the pentose phosphate pathway, the serine biosynthetic pathway, lipogenesis, and the hexosamine pathway. For this reason, glucose transport inhibition is an emerging new treatment for different malignancies, including lung cancer. However, studies both in animal models and in humans have shown high levels of heterogeneity in the utilization of glucose and other metabolites in cancer, unveiling a complexity that is difficult to target therapeutically. Here, we present an overview of different levels of heterogeneity in glucose uptake and utilization in lung cancer, with diagnostic and therapeutic implications.

show abstract

Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes

Cited by 22 publications

References 50 publications

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients

Habitat Imaging-Based 18F-FDG PET/CT Radiomics for the Preoperative Discrimination of Non-small Cell Lung Cancer and Benign Inflammatory Diseases

Heterogeneity of Glucose Transport in Lung Cancer

Contact Info

Product

Resources

About